Hepacor Tablet

L-Ornithine + L-Aspartate
Intas Pharmaceuticals Ltd.
Pack size 10's
Dispensing mode
Source
Agent
Retail Price 11.00 NPR

Available as:

Indications

Hepacor Tablet is used for: Treatment of hyperammonemia due to acute or chronic liver disease, e.g., liver cirrhosis, fatty liver and hepatitis. Treatment of precoma of hepatic encephalopathy.

Adult Dose

Oral 1-2 tab three times a day

Child Dose

Renal Dose

Administration

Contra Indications

Hypersensitivity to L-ornithine-L-aspartate. Severely impaired renal function (renal insufficiency).

Precautions

There are no clinical data available on the use of L-ornithine-L-aspartate in pregnancy. It is not known whether L-ornithine-L-aspartate secreted into breast milk. Therefore, administration of L-ornithine-L-aspartate should be avoided during lactation. Depending on the underlying disease, the ability to drive and operate machines may also be impaired on treatment with L-ornithine-L-aspartate.

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of L-Ornithine + L-Aspartate : Nausea, vomiting, sensation of heat and palpitation. Generally, these symptoms are transient and do not necessitate discontinuation of treatment with L-ornithine-L-aspartate. The symptoms disappear on reduction of the dose or infusion rate.

Mechanism of Action

Note

Hepacor Tablet manufactured by Intas Pharmaceuticals Ltd.. Its generic name is L-Ornithine + L-Aspartate. Hepacor is availble in Nepal. Farmaco Nepal drug index information on Hepacor Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of L-Ornithine + L-Aspartate :